Ascendis Pharma has issued American Depositary Shares (ADS) through an underwritten public offering to raise $150m.
The company also plans to grant the underwriters a 30-day option to buy additional shares worth $22.5m.
Ascendis Pharma plans to use the proceeds towards clinical development, regulatory approval and commercialisation of its TransCon GH product candidate, as well as for general corporate purposes.
The company has appointed J.P. Morgan Securities, Bofa Merrill Lynch and Credit Suisse Securities (USA) as joint book-running managers for the transaction.
DanDrit Biotech USA has issued 2.4 million shares of its common stock in a private placement.
The Denmark-based biopharmaceutical company has also simultaneously issued 1.67 million shares priced at $8 a share in a private placement to raise $13.42m.
DanDrit recently completed the acquisition of biopharmaceutical company Enochian Biopharma .
Pangen Biotech has issued a second series of unregistered and unsecured convertible bonds in a private placement to raise KRW18bn ($16.85m).
Due February 2023, the bonds carry a yield-to-maturity rate of 1%
The South Korean biotechnology company plans to use the proceeds for its on-going operations and investment purposes.
AIT Therapeutics has issued shares and warrants in a private placement to raise $9.82m. A group of investors subscribed to the placement.
The Israeli-based biopharmaceutical company plans to use the proceeds to support its three inhaled nitric oxide (NO) programmes.
The company appointed Laidlaw & Co. (UK) as lead placement agent and Brookline Capital Markets as co-placement agent for the transaction.
The US-based biopharmaceutical company plans to use the proceeds for clinical development of its AB928 and AB122 product candidates, as well as general corporate purposes.
Arcus has selected Citigroup Global Markets , Goldman Sachs & Co and Leerink Partners as joint book-running managers for the transaction and Gunderson Dettmer Stough Villeneuve Franklin & Hachigian as the legal advisor.
The firm has filed a registration statement with the US Securities and Exchange Commission (SEC) for the same.
The underwriters will also be granted an option to buy additional ADS.
The Taiwanese biopharmaceutical company will use the proceeds from the offering towards the development of its TLC590 and TLC178 product candidates, as well as to supplement working capital.